癌症相关血栓形成:台湾人对非维生素K拮抗剂口服抗凝治疗选择的看法。

IF 1.8 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Yu-Yun Shao, Ching-Liang Ho, Cheng-Shyong Chang, Chia-Lun Chang, Jen-Kuang Lee, Hung-Ju Lin, Hui-Hua Hsiao, Ta-Chung Chao, Ching-Yeh Lin, Chuang-Chi Liaw
{"title":"癌症相关血栓形成:台湾人对非维生素K拮抗剂口服抗凝治疗选择的看法。","authors":"Yu-Yun Shao,&nbsp;Ching-Liang Ho,&nbsp;Cheng-Shyong Chang,&nbsp;Chia-Lun Chang,&nbsp;Jen-Kuang Lee,&nbsp;Hung-Ju Lin,&nbsp;Hui-Hua Hsiao,&nbsp;Ta-Chung Chao,&nbsp;Ching-Yeh Lin,&nbsp;Chuang-Chi Liaw","doi":"10.6515/ACS.202303_39(2).20220719A","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer-associated thrombosis (CAT) is a common complication of malignancies. Patients with CAT are at risk of venous thromboembolism recurrence, but also at risk of bleeding while anticoagulated. Taiwanese patients are perceived to have a lower incidence of CAT, likely leading to false reassurance for Taiwanese patients with cancer. Because of this, oncologists and cardiologists from multiple medical institutions in Taiwan have set forth to provide clinical consensus guidelines on the management of CAT, based on local clinical practices and guided by predominant international clinical practice guidelines. This paper aims to describe the current disease burden of cancer-associated venous thromboembolism in Taiwanese cancer patients, and discusses the unmet needs and gaps in the management of this medical complication. It also outlines diagnostic and management strategies relevant to the different treatment options available, such as non-vitamin K antagonist oral anticoagulants.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"242-253"},"PeriodicalIF":1.8000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999188/pdf/acs-39-242.pdf","citationCount":"1","resultStr":"{\"title\":\"Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.\",\"authors\":\"Yu-Yun Shao,&nbsp;Ching-Liang Ho,&nbsp;Cheng-Shyong Chang,&nbsp;Chia-Lun Chang,&nbsp;Jen-Kuang Lee,&nbsp;Hung-Ju Lin,&nbsp;Hui-Hua Hsiao,&nbsp;Ta-Chung Chao,&nbsp;Ching-Yeh Lin,&nbsp;Chuang-Chi Liaw\",\"doi\":\"10.6515/ACS.202303_39(2).20220719A\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer-associated thrombosis (CAT) is a common complication of malignancies. Patients with CAT are at risk of venous thromboembolism recurrence, but also at risk of bleeding while anticoagulated. Taiwanese patients are perceived to have a lower incidence of CAT, likely leading to false reassurance for Taiwanese patients with cancer. Because of this, oncologists and cardiologists from multiple medical institutions in Taiwan have set forth to provide clinical consensus guidelines on the management of CAT, based on local clinical practices and guided by predominant international clinical practice guidelines. This paper aims to describe the current disease burden of cancer-associated venous thromboembolism in Taiwanese cancer patients, and discusses the unmet needs and gaps in the management of this medical complication. It also outlines diagnostic and management strategies relevant to the different treatment options available, such as non-vitamin K antagonist oral anticoagulants.</p>\",\"PeriodicalId\":6957,\"journal\":{\"name\":\"Acta Cardiologica Sinica\",\"volume\":\"39 2\",\"pages\":\"242-253\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999188/pdf/acs-39-242.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Cardiologica Sinica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6515/ACS.202303_39(2).20220719A\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cardiologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6515/ACS.202303_39(2).20220719A","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 1

摘要

癌症相关血栓形成(CAT)是恶性肿瘤的常见并发症。CAT患者有静脉血栓栓塞复发的危险,抗凝治疗时也有出血的危险。台湾患者被认为有较低的CAT发病率,可能导致台湾癌症患者的虚假安心。正因如此,台湾多家医疗机构的肿瘤学家和心脏科专家开始在当地临床实践的基础上,以国际主流临床实践指南为指导,就CAT的管理提供临床共识指南。本文旨在探讨台湾地区癌症相关静脉血栓栓塞病患的疾病负担,并探讨在此医疗并发症的管理上未被满足的需求与差距。它还概述了与不同治疗方案相关的诊断和管理策略,例如非维生素K拮抗剂口服抗凝剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.

Cancer-associated thrombosis (CAT) is a common complication of malignancies. Patients with CAT are at risk of venous thromboembolism recurrence, but also at risk of bleeding while anticoagulated. Taiwanese patients are perceived to have a lower incidence of CAT, likely leading to false reassurance for Taiwanese patients with cancer. Because of this, oncologists and cardiologists from multiple medical institutions in Taiwan have set forth to provide clinical consensus guidelines on the management of CAT, based on local clinical practices and guided by predominant international clinical practice guidelines. This paper aims to describe the current disease burden of cancer-associated venous thromboembolism in Taiwanese cancer patients, and discusses the unmet needs and gaps in the management of this medical complication. It also outlines diagnostic and management strategies relevant to the different treatment options available, such as non-vitamin K antagonist oral anticoagulants.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Cardiologica Sinica
Acta Cardiologica Sinica 医学-心血管系统
CiteScore
2.90
自引率
15.80%
发文量
144
审稿时长
>12 weeks
期刊介绍: Acta Cardiologica Sinica welcomes all the papers in the fields related to cardiovascular medicine including basic research, vascular biology, clinical pharmacology, clinical trial, critical care medicine, coronary artery disease, interventional cardiology, arrythmia and electrophysiology, atherosclerosis, hypertension, cardiomyopathy and heart failure, valvular and structure cardiac disease, pediatric cardiology, cardiovascular surgery, and so on. We received papers from more than 20 countries and areas of the world. Currently, 40% of the papers were submitted to Acta Cardiologica Sinica from Taiwan, 20% from China, and 20% from the other countries and areas in the world. The acceptance rate for publication was around 50% in general.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信